By Andrew Silver

SHANGHAI (Reuters) -Innovent Biologics’ newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction.

Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

Those were introduced in late 2024 and January 2025 respectively, several months after their own approvals, into a Chinese weight-loss drug market that is expected by analysts to be worth billions in the coming years.

While it joined the race late, Innovent’s goals included raising awareness of weight management in society and emphasising the drug’s proven ability to reduce liver

See Full Page